tradingkey.logo
tradingkey.logo
Suchen

Cumberland Pharmaceuticals Inc

CPIX
Zur Watchlist hinzufügen
6.370USD
-0.760-10.66%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
95.27MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Cumberland Pharmaceuticals Inc Unternehmen

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Cumberland Pharmaceuticals Inc Informationen

BörsenkürzelCPIX
Name des UnternehmensCumberland Pharmaceuticals Inc
IPO-datumAug 11, 2009
CEOKazimi (A. J)
Anzahl der mitarbeiter91
WertpapierartOrdinary Share
GeschäftsjahresendeAug 11
Addresse1600 West End Avenue, Suite 1300
StadtNASHVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl37203
Telefon18774842700
Websitehttps://www.cumberlandpharma.com/
BörsenkürzelCPIX
IPO-datumAug 11, 2009
CEOKazimi (A. J)

Führungskräfte von Cumberland Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
4.68K
--
Mr. A. J. Kazimi
Mr. A. J. Kazimi
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Gordon R. Bernard, M.D.
Dr. Gordon R. Bernard, M.D.
Independent Director
Independent Director
--
--
Mr. James L. (Jim) Herman
Mr. James L. (Jim) Herman
Vice President - Trade and Distribution
Vice President - Trade and Distribution
--
--
Mr. Joseph C. Galante
Mr. Joseph C. Galante
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
4.68K
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Cumberland Pharmaceuticals Inc?

Die fünf größten Anteilseigner von Cumberland Pharmaceuticals Inc sind: Mr. Kenneth J. Krogulski

Wie viele Institutionen halten Anteile an Cumberland Pharmaceuticals Inc (CPIX)?

Mit Stand vom 2026Q1 halten 59 Institutionen Anteile an Cumberland Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 2.95M, was 19.66% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1007470.00 gestiegen.

Was ist die größte Einnahmequelle von Cumberland Pharmaceuticals Inc?

Am 2026Q1 erzielte das Geschäft mit Sancuso für Cumberland Pharmaceuticals Inc den höchsten Umsatz in Höhe von 11.91M, was 26.74% des Gesamtumsatzes entspricht.